Company Overview and News

 
AAP MP Sanjay Singh receives Ahmedabad court notice in a defamation case over his allegations in Rafale deal

2018-10-17 financialexpress
Senior AAP leader Sanjay Singh has received notice from a court in Ahmedabad regarding a civil suit filed by Reliance Infrastructure Limited over his allegations in connection with the Rafale deal. Singh asserted he will continue to raise his voice against the Rafale deal “scam” and file his submission before the court. “I have no respect for those toying with security of the country in the name of Bharat Mata.
500390 RELINFRA RELEY RIFS RIFA RELFF

 
Mumbai Metro, PayPal partner for online recharge payments

2018-10-11 freepressjournal.in
Mumbai: Reliance Infrastructure Pvt. Ltd’s Mumbai Metro One has partnered with global digital payments leader PayPal for online recharge payments, marking the latter’s foray into mass transit, an official said here on Thursday.
500390 RELINFRA RELEY RIFS RIFA RELFF

 
Mumbai Metro, PayPal partner for online recharge payments

2018-10-11 financialexpress
Reliance Infrastructure Pvt. Ltd’s Mumbai Metro One has partnered with global digital payments leader PayPal for online recharge payments, marking the latter’s foray into mass transit, an official said here on Thursday. With this, Mumbai Metro commuters can recharge their smart cards on the Reliance Mumbai Metro website or App backed by PayPal’s robust risk and security platform.
500390 RELINFRA RELEY RIFS RIFA RELFF

1
Tata Power among bidders in race for Odisha’s CESU

2018-10-11 livemint
New Delhi: Tata Power Co. Ltd. is among two bidders in the race to acquire Central Electricity Supply Utility of Odisha (CESU Odisha) in what would be the first such deal in nearly two decades in India’s power sector.
RELEY TATAPOWER RIFS 539254 RELFF 500390 RELINFRA TPCL RIFA 500400 AES ADANITRANS

 
HCC wins ₹2,126-cr Mumbai coastal road package II

2018-10-03 thehindubusinessline
The share price of infrastructure major Hindustan Construction Company (HCC) rose 3.8 per cent on Wednesday after the company announced that its joint venture with Hyundai Development Corporation (HDC) has bagged the contract for Package II of Mumbai coastal road worth ₹2,126 crore from the Municipal Corporation of Greater Mumbai (MCGM).
500390 RELINFRA RELEY RIFS RIFA RELFF HIN 500185 HCC

 
HCC venture wins ₹2,126-cr Mumbai Coastal road project

2018-10-03 thehindubusinessline
Infrastructure major Hindustan Construction Company (HCC) in a joint venture with Hyundai Development Corporation has won a contract for Mumbai Coastal road project worth ₹2,126 crore from the Municipal Corporation of Greater Mumbai (MCGM).
500390 RELINFRA RELEY RIFS RIFA RELFF HIN 500185 HCC

 
L&T bags Rs 7,489-cr Mumbai coastal road project

2018-10-01 thehindubusinessline
The work order involves the construction of parts of the Rs 15,000-crore coastal road project from Princess Street Flyover to Baroda Palace.
500390 RELINFRA RELEY RIFS RIFA RELFF HIN 500185 HCC

1
Anil Ambani seeks to sell control of Reliance Communications

2018-09-27 livemint
Reliance Communications Ltd., the telecommunications company that’s offloading most of its assets to a rival, is in talks to sell a controlling stake in what will remain after it exits India’s consumer wireless business.
NMR RELEY RIFS RELFF 1883 532712 500390 RELINFRA 8604 RCOM N33 NRSCF RIFA

 
Reliance Infrastructure Limited - News Clarification

2018-09-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500390 RELINFRA RELEY RIFS RIFA RELFF

 
Reliance Infrastructure Limited - Shareholders meeting

2018-09-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500390 RELINFRA RELEY RIFS RIFA RELFF

 
RInfra AGM: Anil Ambani complains of slow arbitration award payouts

2018-09-18 livemint
Mumbai: Reliance Group chairman Anil Ambani today hit out at government agencies, which owe his debt-laden Reliance Infrastructure Ltd (RInfra) payouts awarded in arbitration.
500390 RELINFRA RELEY RIFS RIFA RELFF

 
Reliance Infrastructure Limited - News Clarification

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500390 RELINFRA RELEY RIFS RIFA RELFF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 75945E109